Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk
Alnylam aims to develop a therapy that targets the INHBE gene and reduces the overall risk of T2D and coronary…
By
Metabolic Disorders
Latest in
Metabolic Disorders
FDA grants Orphan Drug status to Aro Biotherapeutics’ Pompe disease therapy
The company plans to advance ABX1100 into clinical trials in the middle of next year.
Lilly announces results from SURPASS programme for T2D and obesity therapy Mounjaro
Further trials for pediatric and heart failure patients are currently ongoing.
By
Decoding the Covid-19 connection with diabetes
A growing base of evidence suggests people are significantly more likely to develop diabetes in the months following a Covid-19…
By
Lilly’s Mounjaro receives FDA approval for type 2 diabetes treatment
The approval is based on findings from the Phase III SURPASS programme of Mounjaro.
Entrance of novel therapies drives alpha-1 antitrypsin deficiency market growth
The alpha-1 antitrypsin deficiency (AATD) market in the US and Germany is expected to see significant growth from 2021 to…
By
Novartis’ Leqvio can lead cholesterol-lowering space, but barriers remain
Leqvio may surpass its competitors due to its administration convenience and Novartis’ close ties to cardiovascular specialists.
By
Lilly and Evotec enter partnership for metabolic disease drug discovery
Evotec will receive undisclosed upfront, milestone and tiered royalty payments totalling up to $1bn.